PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV · Clinician

Should you choose Wegovy? Heart Health and Obesity | Dr. Dan | Obesity Expert

Clinician17:29Jan 2024

Today’s cheapest Wegovy$208/mo at Sesame Care, an average: a $59/mo subscription billed $708 once a year, with medication billed monthly.Compare all Wegovy prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. Not from the video’s creator.

Our summary

The speaker, who presents as an obesity expert, walks through the SELECT trial, published in the New England Journal of Medicine. He explains that earlier obesity medications and lifestyle change alone have a weak record on heart risk. He says GLP-1 medications appear to reduce inflammation and stabilize arterial plaques. Earlier human trials showed heart benefits, but only in people with diabetes. SELECT asked whether Wegovy at 2.4 mg once per week helps people with obesity but no diabetes.

Published by Dr. Dan | Obesity Expert on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

According to the video, the trial enrolled 17,600 people, who received Wegovy or a placebo for about 40 months (3.3 years). They were given no diet or activity advice. Participants averaged about 62 years old, were mostly male, and had an average BMI near 33. None had diabetes, about two thirds had pre-diabetes, and all had existing heart disease. He says the combined outcome of heart attack, stroke or cardiovascular death favored Wegovy, with an absolute risk reduction of about 1.5% and a number needed to treat of 67. He voices some skepticism about combined outcomes.

Broken out, he reports that heart attacks fell significantly, with a number needed to treat of 100. Stroke and cardiovascular death showed no significant difference, while death from any cause was lower with Wegovy. He says the Wegovy group lost about 9.4% of baseline weight, against under 1% on placebo. Stomach side effects faded over time and gallbladder problems rose, but pancreatitis and kidney disease did not. He concludes that individual benefit looks modest while population-level benefit is larger.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 3:04 The speaker says the SELECT trial tested Wegovy at 2.4 mg once per week in people with obesity and heart disease but no diabetes.
  2. 4:07 He describes a design of 17,600 people on Wegovy or placebo for about 40 months, with no diet or activity advice given.
  3. 5:38 He lists the participants as averaging about 62 years old with a BMI near 33, no diabetes, and prior heart disease.
  4. 8:11 He reports the combined heart outcome had an absolute risk reduction of about 1.5% and a number needed to treat of 67.
  5. 9:45 He says heart attacks dropped significantly, with a number needed to treat of 100, while stroke and cardiovascular death were not significantly different.
  6. 14:23 He argues the benefit looks small for one person but meaningful across large populations, and may not depend only on weight loss.

Key moments

Tap one to play from there.

  1. 0:00 Obesity and heart risk
  2. 0:30 Limitations of past treatments
  3. 1:32 GLP-1 medication benefits
  4. 2:58 The select trial explained
  5. 4:20 Study methodology
  6. 5:39 Participant demographics
  7. 6:46 Trial results
  8. 9:29 Specific risk reductions

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Wegovy
Side effects mentioned
gallbladder

Questions this video answers

Does Wegovy reduce heart attack risk in people without diabetes?

According to the speaker, the SELECT trial found a significant reduction in heart attacks among people with obesity and existing heart disease but no diabetes. He gives a number needed to treat of 100 for heart attacks over about 3.3 years.

What was the SELECT trial and who took part?

He describes it as a trial of 17,600 people given Wegovy at 2.4 mg once per week or a placebo for about 40 months. Participants averaged about 62 years old with a BMI near 33, had no diabetes, and had prior heart disease.

What side effects did the SELECT trial report for Wegovy?

The speaker says the usual stomach issues such as nausea, vomiting, constipation and diarrhea appeared but faded as the study went on. Gallbladder problems increased, while pancreatitis, kidney disease and psychiatric disorders occurred at the same rate as placebo.

How much weight did people lose on Wegovy in the SELECT trial?

He says the Wegovy group lost about 9.4% of baseline weight on average, with no diet or activity counseling. The placebo group lost under 1%.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • GLP-1 heart benefits: which drugs are proven to cut heart attack and stroke risk

    Six GLP-1 brands carry an FDA-approved heart indication: Wegovy, Ozempic, Rybelsus, Mounjaro, Trulicity and Victoza. Only Wegovy has it without diabetes. In the SELECT trial of 17,604 adults with heart disease and overweight, Wegovy cut heart attack, stroke and cardiovascular death from 8.0% to 6.5% (hazard ratio 0.80). Zepbound has no heart indication yet; its outcomes trial reports in 2027. Compounded versions were never tested.

  • Who qualifies for Wegovy and Zepbound? The BMI rules, the conditions, and what your plan adds

    You qualify for Wegovy or Zepbound for weight loss as an adult with a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure or high cholesterol. Wegovy also treats adults with heart disease at BMI 27 and up, and a liver disease called MASH; Zepbound also treats sleep apnea at BMI 30 and up. Insurers often ask for more: Aetna's 2026 policy wants BMI 35 and six months in a weight program, and Medicare's Bridge wants BMI 35, or 30 or 27 with specific conditions.

  • Wegovy 7.2 mg (Wegovy HD): what the higher dose adds, and what it costs

    Wegovy HD is semaglutide at 7.2 mg, three times the standard 2.4 mg dose, in its own pen. In the STEP UP trial it took 18.7% off body weight at 72 weeks against 15.6% for 2.4 mg and 3.9% for placebo, in 1,407 adults with obesity. That puts it within 1.5 points of tirzepatide's head-to-head result and makes it the strongest semaglutide there is. Novo sells it direct for $399 a month, $50 above the standard pen, and it sits above the normal ladder rather than replacing it.

Next steps

Wegovy prices

Insurance

Find more like it

Side effectsDose changeWeigh-in and resultsThe trialsGallbladder

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV